A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

Completed · Phase 2 · Has a placebo group

Conditions studied: Chronic Pruritus, Atopic Dermatitis

In brief

This is a multicenter, randomized, double-blind, placebo-controlled, parallel design study of BLU-5937 for the treatment of chronic pruritus in adult subjects with atopic dermatitis (AD).

Key facts

Study ID
NCT04693195
Run by
Bellus Health Inc. - a GSK company
People needed
142
Starts
2020-12-09
Expected to finish
2021-10-12
Last updated by the study team
2022-10-17

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.